Cybin Announces Grant of U.S. Patent Covering Proprietary Deuterated Psilocybin Analog in its CYB003 ProgramBusiness Wire • 08/15/23
Cybin Initiates Dosing of Final Cohort of its Phase 2 Trial of CYB003 in Major Depressive DisorderBusiness Wire • 08/02/23
Cybin Announces Size and Pricing of Previously Announced Overnight Marketed Public Offering of UnitsBusiness Wire • 08/01/23
Cybin Partners With Worldwide Clinical Trials to Support Future Clinical Development of CYB003 in Major Depressive DisorderBusiness Wire • 07/26/23
Cybin Announces Phase 2 Cohort 5 Dosing Completion of CYB003 in Major Depressive DisorderBusiness Wire • 07/24/23
Cybin Announces Publication of Sponsored Feasibility Study Validating Kernel's Flow1 Neuroimaging Technology Measuring Psychedelic Effects on the BrainBusiness Wire • 07/20/23
Kernel's Revolutionary Neuroimaging Technology, Flow1, Validated in Published Feasibility Study on Measuring Psychedelic EffectsBusiness Wire • 07/20/23
Cybin Announces the Development of a Scalable Psychedelic Facilitation Training Program, EMBARKCTBusiness Wire • 07/12/23
Cybin Inc. Announces Appointment of Aaron Bartlone as Chief Operating OfficerBusiness Wire • 06/29/23
Cybin narrows net loss year-over-year; eyes FDA submission in late 2023Proactive Investors • 06/29/23
Cybin Inc. Reports Fiscal Year 2023 Financial Results and Recent Business HighlightsBusiness Wire • 06/27/23